Evolution of spontaneous portosystemic shunts over time and following aetiological intervention in patients with cirrhosis.

Abstract:

BACKGROUND & AIMS

Spontaneous portosystemic shunts (SPSS) develop frequently in cirrhosis. Changes over time and the effect of aetiological interventions on SPSS are unknown, so we aimed to explore the effect of these variables on SPSS evolution.

METHODS

Patients with cirrhosis from the Baveno VI-SPSS cohort were selected provided a follow-up abdominal CT or MRI scan was available. Clinical and laboratory data were collected at baseline and follow-up. Imaging tests were reviewed to evaluate changes in the presence and size of SPSS (large (L)-SPSS was ≥8 mm) over time. Regarding alcohol- or HCV-related cirrhosis, two populations were defined: cured patients (abstinent from alcohol or successful HCV therapy), and non-cured patients.

RESULTS

A total of 617 patients were included. At baseline SPSS distribution was 22% L-SPSS, 30% small (S)-SPSS, and 48% without (W)-SPSS. During follow-up (median follow-up of 63 months), SPSS distribution worsened: L-SPSS 26%, S-SPSS 32%, and W-SPSS 42% ( <0.001). Patients with worse liver function during follow-up showed a simultaneous aggravation in SPSS distribution. Non-cured patients (n = 191) experienced a significant worsening in liver function, more episodes of liver decompensation and lower transplant-free survival compared to cured patients (n = 191). However, no differences were observed regarding SPSS distribution at inclusion and at follow-up, with both groups showing a trend to worsening. Total shunt diameter increased more in non-cured (52%) than in cured patients (28%). However, total shunt area (TSA) significantly increased only in non-cured patients (74 to 122 mm, <0.001).

CONCLUSIONS

The presence of SPSS in cirrhosis increases over time and parallels liver function deterioration. Aetiological intervention in these patients reduces liver-related complications, but SPSS persist although progression is decreased.

IMPACT AND IMPLICATIONS

There is no information regarding the evolution of spontaneous portosystemic shunts (SPSS) during the course of cirrhosis, and especially after disease regression with aetiological interventions, such as HCV treatment with direct-acting antivirals or alcohol abstinence. These results are relevant for clinicians dealing with patients with cirrhosis and portal hypertension because they have important implications for the management of cirrhosis with SPSS after disease regression. From a practical point of view, physicians should be aware that in advanced cirrhosis with portal hypertension, after aetiological intervention, SPSS mostly persist despite liver function improvement, and complications related to SPSS may still develop.

© 2023 The Authors.

Keywords: Advanced chronic liver disease, Alcohol, Ascites, Collateral vessels, Computed tomography, Hepatic encephalopathy, Hepatitis C virus, Magnetic resonance imaging, Portal hypertension, Sustained virological response

References: J Hepatol. 2016 Oct;65(4):741-747
Gastroenterology. 2017 Nov;153(5):1273-1283.e1
J Hepatol. 2017 Mar;66(3):610-618
J Hepatol. 2016 Oct;65(4):692-699
Dig Liver Dis. 2018 Dec;50(12):1315-1323
J Hepatol. 2020 Mar;72(3):472-480
Hepatol Commun. 2021 Dec;5(12):2080-2095
Medicina (Kaunas). 2022 Aug 10;58(8):
Stat Med. 1984 Jan-Mar;3(1):35-44
Antivir Ther. 2011;16(5):677-84
Liver Transpl. 2018 Apr;24(4):505-515
Gastroenterology. 2016 Jul;151(1):130-139.e2
J Hepatol. 2004 May;40(5):757-65
J Hepatol. 2022 Apr;76(4):959-974
Hepatol Res. 2020 Apr;50(4):512-523
J Hepatol. 2020 Dec;73(6):1415-1424
Lancet. 2019 Apr 6;393(10179):1453-1464
Clin Gastroenterol Hepatol. 2023 Aug;21(9):2308-2317.e7
Cardiovasc Intervent Radiol. 1997 Mar-Apr;20(2):120-4
Scand J Gastroenterol. 2018 Sep;53(9):1107-1113
Dig Liver Dis. 2018 Dec;50(12):1324-1326
J Hepatol. 2020 Dec;73(6):1548-1556
J Gastroenterol. 2023 Apr;58(4):394-404
Transplant Proc. 2015 Jul-Aug;47(6):1866-76
Hepatology. 2020 Mar;71(3):1023-1036
Gastroenterology. 2018 May;154(6):1694-1705.e4
Gastroenterology. 1996 Sep;111(3):701-9
J Clin Exp Hepatol. 2018 Dec;8(4):452-459
Liver Int. 2010 Sep;30(8):1123-30
Diagn Interv Imaging. 2016 Jun;97(6):643-50
Crit Care Med. 2009 Nov;37(11):2939-45
J Gastroenterol. 2013 Jul;48(7):847-55
Clin Infect Dis. 2015 Sep 1;61(5):730-40
J Gastroenterol Hepatol. 2009 Jul;24(7):1276-83
J Gastroenterol. 2009;44(1):76-83
Hepatol Commun. 2018 Feb 09;2(4):437-444
Eur J Gastroenterol Hepatol. 2018 Aug;30(8):967-974
J Hepatol. 2020 Jun;72(6):1140-1150
BMC Gastroenterol. 2022 Mar 19;22(1):130
Gastroenterology. 2018 May;154(6):1569-1571
Therap Adv Gastroenterol. 2020 Sep 29;13:1756284820961287
Ann Hepatol. 2022 May-Jun;27(3):100687
Hepatol Res. 2021 Jan;51(1):51-61
Transpl Int. 1992 Mar;5(1):9-14
Clin Infect Dis. 2020 Dec 17;71(10):2726-2729
Quant Imaging Med Surg. 2021 Aug;11(8):3867-3881
Gastroenterology. 2017 Jan;152(1):142-156.e2

Authors

• Juan G Abraldes |
• Agustín Albillos |
• Anna Baiges |
• Annalisa Berzigotti |
• Lawrence Bonne |
• José Luis Calleja |
• Johannes Chang |
• Anna Darnell |
• Ahmed Elmahdy |
• Rita García-Martínez |
• Joan Genescà |
• Gabriele Ghigliazza |
• Virginia Hernández-Gea |
• Aleksander Krag |
• Vincenzo La Mura |
• Wim Laleman |
• Katharina Lampichler |
• Elba Llop |
• Marta López |
• Gavin Low |
• Geert Maleux |
• Javier Martínez |
• Martin H Maurer |
• Akhilesh Mulay |
• Carmen Picón |
• Marta Poncela |
• Michael Praktiknjo |
• Sergi Quiroga |
• Enrique Ramón |
• Thomas Reiberger |
• Cristina Ripoll |
• Rushabh Shah |
• Macarena Simón-Talero |
• Puneeta Tandon |
• Jonel Trebicka |
• Emmanuel A Tsochatzis |
• Judit Vidal-González |
• Alexander Zipprich |